Literature DB >> 24488257

The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy.

Marije E Hamaker1, M Mitrovic, R Stauder.   

Abstract

The G8 screening tool was developed to separate fit older cancer patients who were able to receive standard treatment from those that should undergo a geriatric assessment to guide tailoring of therapy. We set out to determine the discriminative power and prognostic value of the G8 in older patients with a haematological malignancy. Between September 2009 and May 2013, a multi-dimensional geriatric assessment was performed in consecutive patients aged ≥67 years diagnosed with blood cancer at the Innsbruck University Hospital. The assessment included (instrumental) activities of daily living, cognition, mood, nutritional status, mobility, polypharmacy and social support. In parallel, the G8 was also administered (cut-off ≤ 14). Using a cut-off of ≥2 impaired domains, 70 % of the 108 included patients were considered as having an impaired geriatric assessment while 61 % had an impaired G8. The G8 lacked discriminative power for impairments on full geriatric assessment: sensitivity 69, specificity 79, positive predictive value 89 and negative predictive value 50 %. However, G8 was an independent predictor of mortality within the first year after inclusion (hazard ratio 3.93; 95 % confidence interval 1.67-9.22, p < 0.001). Remarkably, patients with impaired G8 fared poorly, irrespective of treatment choices (p < 0.001). This is the first report on the clinical and prognostic relevance of G8 in elderly patients with haematological malignancies. Although the G8 lacked discriminative power for outcome of multi-dimensional geriatric assessment, this score appears to be a powerful prognosticator and could potentially represent a useful tool in treatment decisions. This novel finding certainly deserves further exploration.

Entities:  

Mesh:

Year:  2014        PMID: 24488257     DOI: 10.1007/s00277-013-2001-0

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  30 in total

Review 1.  Poor-Performance Status Assessment of Patients with Non-small Cell Lung Cancer Remains Vague and Blurred in the Immunotherapy Era.

Authors:  Alex Friedlaender; Giuseppe Luigi Banna; Lucio Buffoni; Alfredo Addeo
Journal:  Curr Oncol Rep       Date:  2019-11-25       Impact factor: 5.075

Review 2.  Treatment of Elderly Patients With Acute Myeloid Leukemia.

Authors:  Xavier Thomas; Caroline Le Jeune
Journal:  Curr Treat Options Oncol       Date:  2017-01

3.  Aging and blood disorders: new perspectives, new challenges.

Authors:  Dominique Bron; Lionel Ades; Tamas Fulop; Valentin Goede; Reinhard Stauder
Journal:  Haematologica       Date:  2015-04       Impact factor: 9.941

4.  Utility of the Geriatric 8 for the Prediction of Therapy-Related Toxicity in Older Adults with Diffuse Large B-Cell Lymphoma.

Authors:  Kana Oiwa; Kei Fujita; Shin Lee; Tetsuji Morishita; Hikaru Tsukasaki; Eiju Negoro; Takanori Ueda; Takahiro Yamauchi
Journal:  Oncologist       Date:  2020-12-30

Review 5.  Unmet needs in the scientific approach to older patients with lymphoma.

Authors:  Dominique Bron; Igor Aurer; Marc P E André; Christophe Bonnet; Dolores Caballero; Claire Falandry; Eva Kimby; Pierre Soubeyran; Emanuele Zucca; Andre Bosly; Bertrand Coiffier
Journal:  Haematologica       Date:  2017-06       Impact factor: 9.941

6.  The prognostic importance of polypharmacy in older adults treated for acute myelogenous leukemia (AML).

Authors:  Kathleen Elliot; Janet A Tooze; Rachel Geller; Bayard L Powell; Timothy S Pardee; Ellen Ritchie; LeAnne Kennedy; Kathryn E Callahan; Heidi D Klepin
Journal:  Leuk Res       Date:  2014-07-07       Impact factor: 3.156

7.  Myelodysplastic Syndromes in the Elderly: Treatment Options and Personalized Management.

Authors:  Sonja Burgstaller; Petra Wiesinger; Reinhard Stauder
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

8.  Innovative approach to older patients with malignant hemopathies.

Authors:  Dominique Bron; Pierre Soubeyran; Tamas Fulop
Journal:  Haematologica       Date:  2016-08       Impact factor: 9.941

9.  Geriatric Assessment-Guided Care Processes for Older Adults: A Delphi Consensus of Geriatric Oncology Experts.

Authors:  Supriya Gupta Mohile; Carla Velarde; Arti Hurria; Allison Magnuson; Lisa Lowenstein; Chintan Pandya; Anita O'Donovan; Rita Gorawara-Bhat; William Dale
Journal:  J Natl Compr Canc Netw       Date:  2015-09       Impact factor: 11.908

10.  Integrating patient-centered factors in the risk assessment of MDS.

Authors:  Rena J Buckstein
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.